Related Experiment Video

Updated: May 26, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Pneumococcal bacteremia in a vaccinated pediatric sickle cell disease population

Angela M Ellison1, Kaede V Ota, Karin L McGowan

  • 1Division of Emergency Medicine, The Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. ellisona@email.chop.edu

The Pediatric Infectious Disease Journal
|January 10, 2012
PubMed

Insights

Pneumococcal bacteremia still occurs in children with sickle cell disease despite vaccines and penicillin. Ongoing vigilance is crucial for preventing serious infections in this vulnerable population.

Area of Science:

  • Pediatric Hematology
  • Infectious Diseases
  • Vaccinology

Background:

  • Sickle cell disease (SCD) patients face high risks of invasive pneumococcal disease.
  • Penicillin prophylaxis and pneumococcal vaccines have reduced disease incidence.
  • The post-heptavalent conjugate vaccine era requires updated understanding of disease risks.

Purpose of the Study:

  • To report on pneumococcal bacteremia in pediatric SCD patients after the introduction of the heptavalent pneumococcal conjugate vaccine.
  • To assess the continued effectiveness of prophylactic measures in SCD.
  • To highlight ongoing challenges in preventing pneumococcal infections.

Main Methods:

  • Retrospective review of pediatric patients with SCD.
  • Analysis of cases with confirmed pneumococcal bacteremia.
  • Evaluation of vaccination status and prophylactic treatment.

Main Results:

  • Pneumococcal bacteremia was observed in pediatric SCD patients in the post-heptavalent vaccine era.
  • Some patients with bacteremia had received recommended vaccinations and prophylaxis.
  • This indicates that current strategies may not fully prevent all invasive pneumococcal infections.

Conclusions:

  • Pneumococcal bacteremia remains a significant concern in pediatric SCD patients.
  • Established prophylactic strategies, including vaccination, are not completely effective.
  • Further research and enhanced surveillance are needed to optimize prevention in this high-risk group.

More Related Videos

Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling08:25

Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling

Published on: April 7, 2015

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness12:21

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness

Published on: September 28, 2022

Related Concept Videos

Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps: